Quel est le prix pour StageZero Life Sciences Ltd. (SZLS)

Le prix pour StageZero Life Sciences Ltd. (SZLS) est $0.02770208

Quelle est la capitalisation boursière pour StageZero Life Sciences Ltd. (SZLS)

La capitalisation boursière pour StageZero Life Sciences Ltd. (SZLS) est $2.92M

StageZero Life Sciences Ltd. (SZLS) Ratio P/S

StageZero Life Sciences Ltd. is a vertically integrated healthcare enterprise specializing in the development and market release of advanced molecular diagnostic tests. These innovative solutions are designed for the proactive detection of diseases and individualized health management, with a particular emphasis on oncology-related conditions across North America. Central to its operations is the proprietary Sentinel Principle platform, which enables the identification of novel biomarkers directly from whole blood samples. Its flagship product, Aristotle, exemplifies this innovation; it's a comprehensive multi-cancer panel that simultaneously screens for numerous cancers from a single blood draw, boasting impressive sensitivity and specificity for each identified malignancy. Beyond Aristotle, the company's portfolio includes ColonSentry, a blood-based test gauging colorectal cancer risk; COVID-19 PCR testing and general blood analysis services; the Prostate Health Index for prostate cancer screening; and BreastSentry, designed to evaluate a woman's susceptibility to breast cancer. Established in 1998, StageZero Life Sciences Ltd. maintains its headquarters in Richmond Hill, Canada.

Année	Ratio P/S	Changez
Pas assez de données pour les dates fournies.

Année

Ratio P/S

Changez

Pas assez de données pour les dates fournies.

Entreprise	Ratio P/S	Différence de Ratio P/S	Pays
Thermo Fisher Scientific Inc. TMO.US	4.72	-	US
Danaher Corporation DHR.US	5.67	-	US
WuXi AppTec Co., Ltd. 603259.SS	-	-	CN
Natera, Inc. NTRA.US	16.40	-	US
IDEXX Laboratories, Inc. IDXX.US	9.55	-	US

Entreprise

Ratio P/S

Différence de Ratio P/S

Pays